Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intellia Thera CS
(NQ:
NTLA
)
23.96
+0.96 (+4.17%)
Streaming Delayed Price
Updated: 10:28 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Intellia Thera CS
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
The Latest Analyst Ratings for Intellia Therapeutics
January 04, 2023
Via
Benzinga
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
December 30, 2022
Both stocks have fallen brutally this year, but only one has a chance to recover soon.
Via
The Motley Fool
7 ‘Next Big Things’ for Investors to Buy for 2023
December 13, 2022
The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown.
Via
InvestorPlace
Ulta Beauty To Rally Around 22%? Here Are 10 Other Price Target Changes For Friday
December 02, 2022
Via
Benzinga
Analyst Ratings for Intellia Therapeutics
December 02, 2022
Via
Benzinga
NTLA Stock Falls as Intellia Therapeutics Announces Public Offering
December 01, 2022
Intellia Therapeutics (NTLA) stock is falling hard on Thursday after the company announced a public stock offering of 6.6 million shares.
Via
InvestorPlace
Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates
November 14, 2022
Via
Benzinga
Recap: Intellia Therapeutics Q3 Earnings
November 03, 2022
Intellia Therapeutics (NASDAQ:NTLA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
7 Analysts Have This to Say About Intellia Therapeutics
October 11, 2022
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings:
Via
Benzinga
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing
November 28, 2022
Here's how Ark Invest's top holdings have performed in 2022.
Via
Investor's Business Daily
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
November 15, 2022
Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.
Via
Benzinga
Earnings Preview For Intellia Therapeutics
November 02, 2022
Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
3 Cathie Wood Stocks to Buy and Hold for 10 Years
October 19, 2022
The risks are formidable, but the chances of a massive gain are too much to pass up.
Via
The Motley Fool
Intellia Therapeutics Shares Are Gaining After Positive Data From Second CRISPR Candidate
September 16, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
The Top 5 Stocks Cathie Wood Is Buying This Week
September 23, 2022
Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago...
Via
Benzinga
5 Top Stocks Cathie Wood Is Buying Right Now
September 19, 2022
Cathie Wood's ARKK is down over 50% YTD, although the fund manager is still continuing her purchases of high conviction companies.
Via
InvestorPlace
SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To Know
September 19, 2022
SVB Leerink has decided to maintain its Outperform rating of Intellia Therapeutics (NASDAQ:NTLA) and raise its price target from $152.00 to $158.00. Shares of Intellia Therapeutics are trading down...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Intellia Therapeutics
September 19, 2022
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings:
Via
Benzinga
This Analyst Cuts PT On Adobe, Plus Barclays Predicts $240 For FedEx
September 19, 2022
Wells Fargo lowered the price target for Adobe Inc. (NASDAQ: ADBE) from $425 to $310. Adobe shares fell 1.2% to $296.04 in pre-market trading.
Via
Benzinga
Why Is Applied Optoelectronics (AAOI) Stock Up 35% Today?
September 16, 2022
Applied Optoelectronics (AAOI) stock is climbing higher on Friday after the company revealed a $150 million asset sale and new brand launch.
Via
InvestorPlace
Why Is Esports Entertainment (GMBL) Stock Down 45% Today?
September 16, 2022
Esports Entertainment (GMBL) stock is falling hard on Friday after the company revealed the pricing of a public stock offering.
Via
InvestorPlace
What Is Going on With Intellia Therapeutics (NTLA) Stock Today?
September 16, 2022
Intellia Therapeutics (NTLA) stock is on the move Friday after releasing positive clinical trial data for two of its drugs.
Via
InvestorPlace
Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies
September 16, 2022
Via
Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
September 01, 2022
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.